Mandy Jackson on Muck Rack

Mandy Jackson

Verified
  • Managing Editor, US Commercial News, Scrip
San Diego
As seen in: Scrip, Dove Medical Press, BioXconomy, Citeline, In Vivo, Medtech Insight, The Pink Sheet, Clinical Leader
I am Managing Editor, US Commercial News, for the Citeline Commercial publication Scrip. Views expressed here are strictly my own.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Mandy

Contact Mandy, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Mandy Jackson’s Biography

Read Full Bio →

Mandy Jackson is the US West Coast Editor for Scrip Intelligence. Her focus is US biotech and pharma, including financial, deal making and clinical trials news. Mandy has been a business news reporter for 15 years, covering biotech and pharma companies, biotech law and commercial real estate. She is based in San Diego, California.

Articles

Mega-Round Surge Leads Big Q2 Venture Funding Boom

|
By Mandy Jackson Verified
| Scrip Verified
Data Mixed For Mid-Sized And Small Rounds Second-quarter 2026 data show biopharma venture capital fundraising surged to its highest level since Q1 2021 with a 68% rise in $100m-plus rounds, led by Isomorphic’s $2.1bn financing.
Open in Who Shared Issue with article?

Blackstone Fills Financing Niche, Backing Big Pharma’s Rapidly Growing Pipelines

|
By Mandy Jackson Verified
| Scrip Verified
LOEs, Trial Costs, M&A Fuel Need For Funding Help Scrip spoke with Paris Panayiotopoulos, senior managing director at Blackstone Life Sciences, about the investment firm’s role in helping big pharma fund their rapidly expanding R&D pipelines.
Open in Who Shared Issue with article?

Bayer’s Business Development Is Fueled By Early Company Connections

|
By Mandy Jackson Verified
| Scrip Verified
Taking Risk Early In Hunt For Big Gains Later Scrip spoke with Bayer executives who head its Co.Lab incubators and focus on oncology business development, Friedemann Janus and Deepa Talpade, about early-stage dealmaking.
Open in Who Shared Issue with article?
See all 2,358 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified